Features | Partner Sites | Information | LinkXpress
Sign In
Ampronix
GLOBETECH PUBLISHING LLC
KOREA E & EX

Vascular Closure Device Preserves the Femoral Artery

By HospiMedica International staff writers
Posted on 28 Feb 2013
Image: The Vascade Vascular Closure System (VCS) (Photo courtesy of Cardiva Medical).
Image: The Vascade Vascular Closure System (VCS) (Photo courtesy of Cardiva Medical).
An innovative extravascular device facilitates entry site closure in patients undergoing percutaneous procedures through the femoral artery.

The Vascade Vascular Closure System (VCS) utilizes a unique delivery system based on a proprietary collapsible disc technology made of a biconvex low-profile nitinol, which provides temporary hemostasis during the procedure, eliminating the need for an intravascular component. Secure and rapid hemostasis is achieved by the deployment of a thrombogenic, resorbable collagen hemostatic coating patch, which accelerates coagulation at the arteriotomy site in the femoral artery by expanding approximately 13 times in volume, thus ensuring that the residual tissue tract is sufficiently filled and provides mechanical hemostasis.

The VCS is indicated for femoral arterial access site closure while reducing times to hemostasis and ambulation in patients who have undergone diagnostic or interventional endovascular procedures using a procedural sheath. The simple-to-use technique avoids the need for sheath exchange or added complexity, enabling deployment in as little as 30 seconds. The Vascade VCS is a product of Cardiva Medical (Sunnyvale, CA, USA), and has been approved by the US Food and Drug Administration (FDA).

“Vascade is a new generation of extravascular closure technology that offers significant advantages over conventional closure devices and manual compression,” said Frank Zidar, MD, of the Heart Hospital of Austin (TX, USA). “I am excited to be able to provide Vascade to my patients and to integrate it into my practice.”

The safety and effectiveness of Vascade VCS was evaluated in 420 patients across 21 clinical sites (up to 30 days post diagnostic or interventional procedures), that showed that the system is more effective than manual compression for mean time for hemostasis (TTH) and mean time to ambulation (TTA), and with fewer complications.

Related Links:

Cardiva Medical



Inditherm
Harloff
JD Honigberg International

Channels

Critical Care

view channel

Little Evidence Supports Opioid Use for Chronic Pain

A new study reveals that there is paltry evidence for the long-term safety and efficacy of opioids in the treatment of chronic pain. Researchers at the Oregon Health & Science University (OHSU; Portland, USA) and the University of Washington (Seattle, USA) searched MEDLINE, the Cochrane Central Register of Controlled... Read more

Women's Health

view channel

Pregnant Women in Austria Experience Iodine Deficiency

A new study suggests that pregnant women in Austria have a potentially clinically significant iodine deficiency which could impair embryonic brain development. Researchers at the Medical University of Vienna (Austria) conducted a cross-sectional investigation of urinary iodine excretion in 246 pregnant women (2 in the... Read more

Health IT

view channel

Computer Model Predicts Public Response to Disease Outbreaks

A new computer model could help public health officials anticipate public reactions to disease outbreaks, based on a combination of data collected from hospitals, social media, and other sources. Researchers at MIT (Cambridge, MA, USA), the Draper Laboratory (Cambridge, MA, USA), and Ascel Bio (Larchmont, NY, USA),... Read more

Business

view channel

Abbott Completes Topera Acquisition

Abbott (Abbott Park, IL, USA) has completed its acquisition of Topera (Menlo Park, CA, USA), developer of innovative electrophysiology technologies for the diagnosis and treatment of atrial fibrillation (AF). The Topera rotor identification system helps physicians identify and target patient-specific rotors that have... Read more
 

Events

05 Mar 2015 - 08 Mar 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.